Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Legal Officer

SVP, Chief Business Officer

CMO,SVP,Head-Res&Drug

Chief Executive Officer

SVP, Chief Financial Officer

Principal Accounting Officer

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-15	Premium	acquired	Premium	Premium	Premium	-
2024-03-08	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-03-08	Premium	acquired	Premium	Premium	Premium	SVP, Chief Business Officer
2024-03-08	Premium	acquired	Premium	Premium	Premium	CMO,SVP,Head-Res&Drug
2024-03-08	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-03-08	Premium	acquired	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-03-06	Premium	bought	Premium	Premium	Premium	-
2024-03-05	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-03-04	Premium	bought	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Principal Accounting Officer
2024-02-12	Premium	acquired	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-02-12	Premium	acquired	Premium	Premium	Premium	SVP, Chief Business Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	SVP, Chief Business Officer
2024-02-12	Premium	acquired	Premium	Premium	Premium	Principal Accounting Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	CMO,SVP,Head-Res&Drug
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-12	Premium	acquired	Premium	Premium	Premium	CMO,SVP,Head-Res&Drug
2024-02-12	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-08	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Financial Officer
2024-01-17	Premium	acquired	Premium	Premium	Premium	CMO,SVP,Head-Res&Drug
2024-01-17	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-01-17	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-17	Premium	acquired	Premium	Premium	Premium	SVP, Chief Financial Officer
2023-12-15	Premium	acquired	Premium	Premium	Premium	-

IRWD - Ironwood Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for IRWD